Novome Biotechnologies Inc. wasn’t out shaking the trees looking for a partner in its drive to develop cellular therapies for the gut to treat chronic diseases but it found one in Genentech Inc., which was familiar with Novome’s founding work at Stanford University. Now the two have struck a multiyear collaboration to discover, engineer and develop bacterial strains expressing and delivering molecules to targets in the intestinal tract to treat diseases such as inflammatory bowel disease. Read More
Yumanity Therapeutics Inc. CEO Richard Peters said his firm is “in the driver’s seat” with regard to partnering options or going it alone, after YTX-7739 hit the primary endpoints in a phase Ib Parkinson’s disease (PD) study. Wall Street seemed less than certain about the success, knocking shares (NASDAQ: YMTX) down $2.83, or 33.4%, to close at $5.65. Read More
LONDON – A pilot study has shown that whole genome sequencing can pinpoint the genetic causes of rare diseases, even in people who had previously not been given a diagnosis after undergoing sequencing of their protein coding exome. Read More
Continuing its downward trend, BioWorld’s Cancer Index (BCI) has fallen by 19.16% this year, a stark contrast with the broader Nasdaq Biopharmaceutical Index and the Dow Jones Industrial Average, both of which are tracking up by 4.49% and 19.03%, respectively. Read More
DUBLIN – Sisaf Ltd. has exercised an option on an Italian preclinical program to treat a rare bone disorder, autosomal dominant osteopetrosis type 2, with an siRNA molecule, which it will deliver with its in-house Bio-courier technology. Read More
After signing a potential $1.2 billion cell therapy deal with Vertex Pharmaceuticals Inc. in August, Arbor Biotechnologies Inc. has raised $215 million in series B financing to advance next-generation precision gene editing therapeutics. Read More
Investors were thrilled when Roche Holding AG subsidiary Genentech Inc. and AC Immune SA reported top-line results from the Lauriet trial on Aug. 31, giving a positive jolt to AC Immune’s stock on the day of the announcement. At the Clinical Trials in Alzheimer’s Disease 2021 meeting, the reaction of the medical community was more skeptical. Read More
Kaléo Inc. agreed to pay $12.7 million to end whistleblower allegations that the Richmond, Va.-based company caused the submission of false claims for Evzio (naloxone hydrochloride), an injectable drug used to reverse opioid overdoses. Read More
New hires and promotions in the biopharma industry, including: Asgard, Beyondspring, Cyrano, Finch, Freeline, Home, Intima, Ocuterra, Saliogen, Sitryx. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Astrazeneca, Bergenbio, Dragonfly, Glaxosmithkline, Inovio, Moderna, Pharmaxis, Plus. Read More
